Previous 10 | Next 10 |
2023-11-01 06:04:01 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter...
United Therapeutics Corporation (UTHR) is expected to report $4.89 for Q3 2023
2023-11-01 04:17:37 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amid Generic Threat United Therapeutics: Fundamental, Technical Analyses Justify A Buy Decision United Therapeutics Q3 2023 Earnings Preview United Therapeutics ...
2023-10-31 12:39:29 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...
Up to 60,000 patients in the United States may have PPF, with only one approved therapy available United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, whi...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the UBS Biopharma Co...
2023-10-31 02:17:12 ET Summary I will recap the eleven partnership deals MannKind has been involved in over its operation as a corporation. I will share my opinion as it relates to the current status of these eleven partnerships. I will discuss why it is my opinion that MannKi...
2023-10-30 06:33:26 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...
United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. ...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...